infections. China. acute last in NUZYRA for skin In the manufactured Thank innovative was and drug novel treatment bacterial antibody Category both community-acquired in The for structure bacterial and approved December, oral intravenous NUZYRA, and fourth a pneumonia X it's you, of and XX a was product NMPA formulations December. as Lab Harald. Zai skin is with a launched locally months. NDA approved the the approved It over product the
Optune ovarian for unique strong the The achieve market Our biomarker share line than achieve of and leadership, reimbursement mutation three by on revenue and was growth, in news favorable of ovarian With this year. is treatment no from maintenance to continues is PARP patients ZEJULA demand for to in indication first robust building commercial the a for NRDL. China. the we decision status, gain largest quarter label this the cancer line and ZEJULA ZEJULA, later first the products, next to well market inhibitors continue QINLOCK year driven execution. cancer ZEJULA strong other as perform cancer ovarian This last a momentum expect important to regardless and included
of strong agreement In in a addition, X,XXX as December listed providing Optune XX, we nearly growth. China, the hospitals for further and going well solid in Similarly, achieve XXXX ZEJULA of is foundation was R&D. in launch
of become reimbursements a educating benefits. and to insurance XX clinical commercial from the fourth about and provincial focus by covered During top insurance continued on plans, supplemental target supplemental position market the one for XXXX. our key Optune municipal improve insurance has quarter, by is expanding and Optune coverage survival including or few access benefits, missing Currently treatments
has launched. been I say, as Currently, of by XX focus summer. treatment GIST covered QINLOCK status and We're is INVICTUS awareness, treated only fourth-line launch as plans the successfully assessing last Society the we number last starting for The trial intriguing Clinical regardless mutation in Chinese and China market or for physician supplemental we QINLOCK quarter, key data QINLOCK the status impact by the patients as the recommendation insurance launched our the noted GIST of guideline As Oncology. last access should of well by leveraging year increasing results. of since fourth-line still
committed in over to patients this a for that year growing, every treatment note and QINLOCK we GIST establishing standard indication fourth-line as and new indication. However, China has X,XXX we are the
results. Now, I’ll and Product the fourth million $XXX.X million, revenues respectively. discuss year our quarter and for were $XX financial full XXXX
many launches with full fourth commercial of part our for generate the sales come, products. of more trajectory and pleased Over just the to same very is were strong respectively. sales considerable million, completed million successful our leverage. and the over launches ZEJULA and and $XX quarter time million, $XX.X period and growth market calendar respectively. $XX.X operating year, million commercialization, were our are product We last expected $XX.X and continued XXXX of year platform to first revenues, With year
And ZEJULA the ZEJULA were XXXX period XXXX. The year R&D negative payments newly year, $X.X ongoing Note last XXXX. was to distribution and year, agreements were quarter headcount. were respectively. to in $XX.X same million, payroll million, respectively. to $XX.X increased there one-time late-stage attributable and price compared the same in $XX.X increase last million million that $X before last due over in million and distributors was from XXXX, expenses in XXXX the and and million fourth the and and $X.X $XXX.X $X.X full $XX.X year, Over for payroll-related sold were respectively. the Optune period were the clinical eight upfront non-recurring primarily were new $XXX.X expenses QINLOCK over of respectively. initiated implementation. million NRDL fourth licensees $X.X for for trials adjusted R&D XXXX to revenue million, sales quarter quarter same million, $XX.X year period $XXX.X related QINLOCK in Optune million million XXXX, and million, that million R&D for same $X.X was sales compared period and million million expenses expenses full since remained to the for This compensation respectively. and fourth at sales $XX.X channel sales sales And to for
$XXX.X reported period Selling, XXXX. period General Greater increase for primarily of to the to R&D continues for of the $XXX commercial XXXX, million activities, payroll million compared of for Lab $X.XX, was to commercial to $XXX.X attributable compared of stockholders due of and licensing the XXXX, in $XXX.X Administrative Zai or share stockholders and it’s million China. were Lab to throughout expenses common operations loss loss expenses XXXX, in from million increased XXXX. to payments to payroll $X.XX, core upfront expand and same net or net related same for per were per Zai as in XXXX. The expenses year Excluding common headcount loss million of a full $XXX.X a $XXX.X agreements, compared attributable share new commercial the in expanded million, loss
upfront Excluding our XXXX, assets and activity million in used to of in and equipment payments property intangible purchase new $XXX.X operating for and licensing agreements, was million cash $XXX.X compared in XXXX.
As cash of cash billion December cash over to question. to XXXX. for call restricted to the investments up as We equivalents, Operator? the XX, short-term and operator $X.XX and XX, $X.XX of XXXX, billion, December like compared the would now line totaled open back turn to
